A VISIONaerie® approach
We discover, develop, and commercialize first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases, and retinal diseases.
Learn MoreJoin us in creating the future of eye care!
Our Products
We currently market two innovative prescription eye drops for lowering intraocular pressure (IOP) in glaucoma.
Learn More
Our Research
We are making significant progress in developing new treatments for dry eye and retinal diseases.
Learn More
STOCK Quote
NASDAQ: AERI
$12.94USD
Sep 17, 4:00 PM ET
Latest News
Aerie Pharmaceuticals Announces Novel Dry Eye Product Candidate AR-15512 (TRPM8 Agonist) Ophthalmic Solution Achieved Statistical Significance Over Multiple Symptoms and Signs in Successful Phase 2b...
Aerie Pharmaceuticals to Announce Second Quarter 2021 Financial Results and Host Conference Call on Wednesday, August 4, 2021
Aerie Pharmaceuticals Completes Enrollment of its first Phase 3 Clinical Trial of Netarsudil Ophthalmic Solution in Japan
DISCOVaerie™ Live!
Visit our virtual destination for the eye care community to get informed and connected.
MORE
CAREERS AT AERIE
We are looking for VISIONaerieS® who share our passion for innovation to protect sight.
MORE
OUR ESG COMMITMENT
Aerie is dedicated to environmental stewardship, social responsibility, and good corporate governance.
MORE